165 related articles for article (PubMed ID: 32072462)
1. The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies.
Marschallinger J; Altendorfer B; Rockenstein E; Holztrattner M; Garnweidner-Raith J; Pillichshammer N; Leister I; Hutter-Paier B; Strempfl K; Unger MS; Chishty M; Felder T; Johnson M; Attems J; Masliah E; Aigner L
Neurotherapeutics; 2020 Jul; 17(3):1061-1074. PubMed ID: 32072462
[TBL] [Abstract][Full Text] [Related]
2. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease.
Wallin J; Svenningsson P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070609
[TBL] [Abstract][Full Text] [Related]
3. Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.
Dey M; Singh RK
Pharmacology; 2021; 106(9-10):469-476. PubMed ID: 34350893
[TBL] [Abstract][Full Text] [Related]
4. The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice.
Michael J; Zirknitzer J; Unger MS; Poupardin R; Rieß T; Paiement N; Zerbe H; Hutter-Paier B; Reitsamer H; Aigner L
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803482
[TBL] [Abstract][Full Text] [Related]
5. Montelukast alleviates inflammation in experimental autoimmune encephalomyelitis by altering Th17 differentiation in a mouse model.
Han B; Zhang YY; Ye ZQ; Xiao Y; Rasouli J; Wu WC; Ye SM; Guo XY; Zhu L; Rostami A; Wang LB; Zhang Y; Li X
Immunology; 2021 Jun; 163(2):185-200. PubMed ID: 33480040
[TBL] [Abstract][Full Text] [Related]
6. Cysteinyl leukotriene receptor-1 as a potential target for host-directed therapy during chronic schistosomiasis in murine model.
Mosala P; Mpotje T; Abdel Aziz N; Ndlovu H; Musaigwa F; Nono JK; Brombacher F
Front Immunol; 2024; 15():1279043. PubMed ID: 38840916
[TBL] [Abstract][Full Text] [Related]
7. Ameliorating effect of leukotriene receptor antagonist in multi-organ toxicity induced in rat offspring, a possible role for epidermal growth factor.
Abdelzaher WY; Rofaeil RR; Abdel-Hafez SMN; Atta M; Bahaa El-Deen MA; Ali DM
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):183-191. PubMed ID: 33504223
[No Abstract] [Full Text] [Related]
8. Leukotriene receptor antagonism with montelukast as a possible therapeutic for venous thromboembolism prophylaxis: An observational study.
Sutton SS; Magagnoli J; Cummings TH; Hardin JW
Prostaglandins Other Lipid Mediat; 2022 Aug; 161():106649. PubMed ID: 35595009
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the cysteinyl leukotriene pathways increases survival of RGCs and reduces microglial activation in ocular hypertension.
Trost A; Motloch K; Koller A; Bruckner D; Runge C; Schroedl F; Bogner B; Kaser-Eichberger A; Strohmaier C; Ladek AM; Preishuber-Pfluegl J; Brunner SM; Aigner L; Reitsamer HA
Exp Eye Res; 2021 Dec; 213():108806. PubMed ID: 34715090
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms underlying the protective effect of leukotriene receptor antagonist montelukast against doxorubicin induced testicular injury in rats.
Mohamed MZ; Zenhom NM
Prostaglandins Other Lipid Mediat; 2020 Aug; 149():106447. PubMed ID: 32173485
[TBL] [Abstract][Full Text] [Related]
11. Montelukast in pediatric asthma management.
Walia M; Lodha R; Kabra SK
Indian J Pediatr; 2006 Apr; 73(4):275-82. PubMed ID: 16816486
[TBL] [Abstract][Full Text] [Related]
12. Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity.
Al-Kuraishy HM; Al-Gareeb AI; Almulaiky YQ; Cruz-Martins N; El-Saber Batiha G
Eur J Pharmacol; 2021 Aug; 904():174196. PubMed ID: 34004207
[TBL] [Abstract][Full Text] [Related]
13. The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.
Hoxha M; Rovati GE; Cavanillas AB
Eur J Clin Pharmacol; 2017 Jul; 73(7):799-809. PubMed ID: 28374082
[TBL] [Abstract][Full Text] [Related]
14. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice.
Lai J; Hu M; Wang H; Hu M; Long Y; Miao MX; Li JC; Wang XB; Kong LY; Hong H
Neuropharmacology; 2014 Apr; 79():707-14. PubMed ID: 24456746
[TBL] [Abstract][Full Text] [Related]
15. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier.
Zhou L; Sun X; Shi Y; Liu J; Luan G; Yang Y
Inflammopharmacology; 2019 Oct; 27(5):933-940. PubMed ID: 31313075
[TBL] [Abstract][Full Text] [Related]
16. Influence of leukotriene pathway polymorphisms on clinical responses to montelukast in Japanese patients with asthma.
Kotani H; Kishi R; Mouri A; Sashio T; Shindo J; Shiraki A; Hiramatsu T; Iwata S; Taniguchi H; Nishiyama O; Iwata M; Suzuki R; Gonda H; Niwa T; Kondo M; Hasegawa Y; Kume H; Noda Y
J Clin Pharm Ther; 2012 Feb; 37(1):112-6. PubMed ID: 21385196
[TBL] [Abstract][Full Text] [Related]
17. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.
Shimbori C; Shiota N; Okunishi H
Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736
[TBL] [Abstract][Full Text] [Related]
18. Montelukast: more than a cysteinyl leukotriene receptor antagonist?
Tintinger GR; Feldman C; Theron AJ; Anderson R
ScientificWorldJournal; 2010 Dec; 10():2403-13. PubMed ID: 21170491
[TBL] [Abstract][Full Text] [Related]
19. Montelukast Ameliorates 2K1C-Hypertension Induced Endothelial Dysfunction and Associated Vascular Dementia.
Gupta S; Singh P; Sharma B
Curr Hypertens Rev; 2024; 20(1):23-35. PubMed ID: 38192137
[TBL] [Abstract][Full Text] [Related]
20. Montelukast, a cysteinyl leukotriene receptor antagonist, exerts local antinociception in animal model of pain through the L-arginine/nitric oxide/cyclic GMP/K
Alizamani E; Ghorbanzadeh B; Naserzadeh R; Mansouri MT
Int J Neurosci; 2021 Oct; 131(10):1004-1011. PubMed ID: 32408781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
